The Safety,Efficacy of Anti-EGFR Humanized Monoclonal Antibody Combined With Chemotherapy in Advanced Solid Tumors.

NCT ID: NCT03577704

Last Updated: 2023-04-12

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE1/PHASE2
• Total Enrollment: 56 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2018-08-08
• Study Completion Date: 2022-12-30

Brief Summary

HLX07 is a new anti-EGFR monoclonal antibody (mAb) with improved glycosylation pattern.In pre-clinical efficacy studies, HLX-07 is either equivalent or more potent than cetuximab in multiple cancer models without increased toxicities.This study is an open-labeled, dose-escalation study designed to explore the maximum tolerated dose (MTD) and safety of HLX07 in combination with different chemotherapy regimens.

Detailed Description

This study is a parallel 3-arm escalation trial with 3 doses of HLX07 (400 mg, 600 mg, or 800 mg per single dose) combined with 3 different fixed-dose chemotherapy regimens.

Three chemotherapy regimens are：

① Gemcitabine (1000 mg/m2) and Cisplatin (75 mg/m2) , every three weeks. Gemcitabine was administered on the first day and on the 8th day, and cisplatin 75 mg/m2 was administered on the first day , a total of 4-6 cycles。

② Paclitaxel (80 mg/m2) and carboplatin (AUC=2), every 3 weeks. Paclitaxel and carboplatin were administered on days 1, 8 and 15 for a total of 4-6 cycles.

③ mFOLFOX6 protocol: oxaliplatin (85 mg/m2), leucovorin (400 mg/m2), and 5-fluouracil (5-FU) (400 mg/m2, followed by 2400 mg/m2), every 2 weeks. Oxaliplatin, leucovorin and 5-FU were administered on the first day.

After 4 to 6 cycles of (gemcitabine and cisplatin regimens) and (the paclitaxel and carboplatin regimens) or after 6 to 12 cycles of the mFOLFOX6 regimen, well-controlled patients will be continue to receive a weekly HLX07 infusion as maintenance therapy for maximum 2 years or until disease progression or emergence of intolerable toxicity or permanent withdrawal or death (whichever comes first).

The study used the Bayes optimal interval design (BOIN) to determine the MTD of HLX07 in combination with chemotherapy.

Conditions

Advanced Solid Tumors

Study Design

• Allocation Method: NON_RANDOMIZED
• Intervention Model: SEQUENTIAL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

HLX07+Gemcitabine+Cisplatin arm

HLX07 is given on D1,D8,D15 combine with Gemcitabine (1000 mg/m2) and Cisplatin (75 mg/m2) in 3 weeks- cycles for 4-6 cycles .Gemcitabine was administered on the D1 and D8 and cisplatin 75 mg/m2 was administered on the D1. After 4-6 cycles of combination therapy, once weekly HLX07 infusion will be continue for a maximum duration of 2 years or until disease progression or emergence of intolerable toxicity or permanent withdrawal or death (whichever comes first).

In each cohort, HLX07 will use BOIN design to assign the subject's dose level and determine the MTD.

Group Type: EXPERIMENTAL

HLX07+Gemcitabine+Cisplatin

Intervention Type: DRUG

Recombinant anti-EGFR humanized monoclonal antibody in combination with Gemcitabine and Cisplatin.

HLX07, IV, weekly.

HLX07+Paclitaxel+Carboplatin arm

HLX07 is given on D1,D8,D15 combine with Paclitaxel (80 mg/m2) and carboplatin (AUC=2) in 3 weeks-cycle for 4-6 cycles .Paclitaxel and carboplatin were administered on D1, D8 and D15. After 4-6 cycles of combination therapy, once weekly HLX07 infusion will be continue for a maximum duration of 2 years or until disease progression or emergence of intolerable toxicity or permanent withdrawal or death (whichever comes first).

In each cohort, HLX07 will use BOIN design to assign the subject's dose level and determine the MTD.

Group Type: EXPERIMENTAL

HLX07+Paclitaxel+Carboplatin

Intervention Type: DRUG

Recombinant anti-EGFR humanized monoclonal antibody in combination with Paclitaxel and Carboplatin.

HLX07, IV, weekly.

HLX07+mFOLFOX6 arm

HLX07 is given on D1,D8 combine with mFOLFOX6 ( oxaliplatin (85 mg/m2), leucovorin (400 mg/m2), and 5-FU (400 mg/m2, followed by 2400 mg/m2) in 2 weeks-cycles for 6-12 cycles . Oxaliplatin, leucovorin and 5-FU were administered on D1. After 6-12 cycles of combination therapy,once weekly HLX07 infusion will be continue for a maximum duration of 2 years or until disease progression or emergence of intolerable toxicity or permanent withdrawal or death (whichever comes first).

In each cohort, HLX07 will use BOIN design to assign the subject's dose level and determine the MTD.

Group Type: EXPERIMENTAL

HLX07+mFOLFOX6

Intervention Type: DRUG

Recombinant anti-EGFR humanized monoclonal antibody in combination with Oxaliplatin, Calcium Folinate and 5-FU.

HLX07, IV, weekly.

Interventions

HLX07+Gemcitabine+Cisplatin

Recombinant anti-EGFR humanized monoclonal antibody in combination with Gemcitabine and Cisplatin.

HLX07, IV, weekly.

Intervention Type: DRUG

HLX07+Paclitaxel+Carboplatin

Recombinant anti-EGFR humanized monoclonal antibody in combination with Paclitaxel and Carboplatin.

HLX07, IV, weekly.

Intervention Type: DRUG

HLX07+mFOLFOX6

Recombinant anti-EGFR humanized monoclonal antibody in combination with Oxaliplatin, Calcium Folinate and 5-FU.

HLX07, IV, weekly.

Intervention Type: DRUG

Other Intervention Names

Recombinant anti-EGFR humanized monoclonal antibody; Gemzar; Cisplatin; Recombinant anti-EGFR humanized monoclonal antibody; Paclitaxel; Carboplatin; Recombinant anti-EGFR humanized monoclonal antibody; Oxaliplatin for Injection; Folinic acid calcium salt hydrate; 5-fluouracil

Eligibility Criteria

Inclusion Criteria

1. Patients with histologically confirmed metastatic or recurrent advanced solid tumors which has indication to receive treatment with one of above three chemotherapy regimens.The lesions must be assessable based on the RECIST v1.1 criteria.The number of previously received chemotherapy regimens should not exceed two.

2. At least 28 days from prior major surgery, prior cytotoxic chemotherapy, or prior therapy with investigational agents or local radiotherapy and at least 42 days from the last infusion of immune check point inhibitors (The antibodies or drugs include but not limited to IDO, PD-1, PD-L1, IL-2R, CTLA-4, CD137, and GITR) before the first infusion of investigational product.

3. Eastern Cooperative Oncology Group (ECOG) score ≤ 1,

4. Expected survival time ≥ 3 months;

5. Has sufficient hematological function, defined as: neutrophil absolute value ≥ 1.5 × 109 / L; hemoglobin level ≥ 9.0 g / dL ; Platelet count ≥100×109 /L.

6. Has sufficient liver function, defined as: total bilirubin level ≤ 1.5 × upper limit of normal (ULN); aspartate aminotransferase (AST) and alanine aminotransferase (ALT) levels ≤ 2.5 × ULN, For patients with known liver metastases or primary hepatocellular carcinoma patients ≤ 5 x ULN.

7. Has adequate coagulation function defined as: International normalized ratio (INR) ≤ 1.5 or prothrombin time (PT) ≤ 1.5 x ULN, and activated partial thromboplastin time (PTT) in the absence of anticoagulant therapy /aPTT) ≤ 1.5 x ULN.

8. Has adequate cardiac function, defined as: left ventricular ejection fraction (LVEF) ≥ 50%.

9. Has sufficient renal function; in patients receiving the gemcitabine plus cisplatin regimen is defined as creatinine clearance ≥ 60 ml/min and in patients receiving the paclitaxel plus carboplatin regimen or the mFOLFOX6 regimen, is defined as creatinine clearance ≥ 50 ml/min (calculated by the Cockcroft-Gault formula).

10. Use of effective contraceptive measures if procreative potential exists.

11. Able to provide written informed consent.

Exclusion Criteria

1. Concurrent unstable or uncontrolled medical conditions. Either of the followings:

• Active systemic infections;
• Poorly controlled hypertension (systolic blood pressure ≥ 160 mmHg or diastolic blood pressure ≥100 mmHg), or poor compliance with anti-hypertensive agents;
• Clinically significant arrhythmia, unstable angina pectoris, congestive heart failure (class III or IV of New York Heart Association (NYHA)) or acute myocardial infarction within 6 months;
• Uncontrolled diabetes or poor compliance with hypoglycemic agents;
• The presence of chronically unhealed wound or ulcers;
• Other chronic diseases, which, in the opinion of the investigator, could compromise safety of the patient or the integrity of study.

2. Unstable central nervous system (CNS) metastasis. Patients who have previously undergone surgery or radiotherapy for brain metastases may participate in this study if they are clinically stable for at least 4 weeks and has stopped steroids for at least 2 weeks prior to the first infusion of the test drug and there is no new evidence of progression.

3. Has primary central nervous system malignancy;

4. Known patients have drug allergies to specific drug regimens (eg anti-EGFR monoclonal antibodies, gemcitabine, platinum, paclitaxel, fluorouracil allergy);

5. known active hepatitis B or C infection (active hepatitis B is defined as hepatitis B surface antigen HBsAg positive and Hepatitis B virus (HBV) DNA> 500 copies / ml; active hepatitis C is defined as hepatitis C antibody-positive and / or quantitative Hepatitis C virus (HCV) RNA results positive);

6. Human immunodeficiency virus infection .

7. Pregnancy or breast-feeding woman.

8. Patients with colorectal cancer whose tumors have K-ras, N-ras, or B-raf mutations;

9. The patient has a history of alcohol abuse or drug abuse;

10. Use of herbal medicine within the first 2 weeks before the first infusion of the test drug;

11. Treatment with systemic steroids (equivalent to >10 mg/day of methylprednisolone) or any other form of immunosuppressive therapy within 2 weeks of the first infusion of the test drug;

12. Patient has a history or current evidence of any condition or disease that could confound the results of the study, or is not the best interest of the patient to participate, in the opinion of Investigator.

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 75 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Shanghai Henlius Biotech

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Jin E Li, PhD

Role: PRINCIPAL_INVESTIGATOR

No.1800 Yuntai Road,Pudong District,Shanghai

Locations

Shanghai East Hospital

Shanghai, Shanghai Municipality, China

Countries

China

References

M.M. Hou, C.L. Ho, H.Y. Lin, W. Jiang, S. Liu, Y. Hong, A. Luk, S.F. Lin, T.C. Hsieh, E. Liu. A novel anti-EGFR antibody HLX07 for potential treatment of squamous cell carcinoma of the head and neck. Annals of Oncology. Volume 30 | Supplement 9 | November 2019.

Reference Type: BACKGROUND

Related Links

https://doi.org/10.1093/annonc/mdz420.007

ESMO Asia 2019 (Poster); Annals of Oncology

Other Identifiers

HLX07-002

Identifier Type: -

Identifier Source: org_study_id